XNCR

Xencor, Inc.

12.11

USD

XNCR Earnings Reports

Positive Surprise Ratio

XNCR beat 30 of 41 last estimates.

73%

Next Report

Date of Next Report

May 05, 2026

Estimate for Q1 26 (Revenue/ EPS)

$32.30M

-$0.75

Implied change from Q4 25 (Revenue/ EPS)

+14.39%

+733.33%

Implied change from Q1 25 (Revenue/ EPS)

-1.32%

+13.64%

Xencor, Inc. earnings per share and revenue

On Feb 25, 2026, XNCR reported earnings of -0.09 USD per share (EPS) for Q4 25, beating the estimate of -0.61 USD, resulting in a 85.37% surprise. Revenue reached 28.24 million, compared to an expected 32.32 million, with a -12.63% difference. The market reacted with a +13.11% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 11 analysts forecast an EPS of -0.75 USD, with revenue projected to reach 32.30 million USD, implying an increase of 733.33% EPS, and increase of 14.39% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Nektar Therapeutics

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$2.52

Actual

-$1.78

Surprise

+29.47%

Savara Inc.

Report Date

Mar 13, 2026 For Q4 25

Estimate

-$0.12

Actual

-$0.13

Surprise

-8.15%

Lyell Immunopharma, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$2.27

Actual

-$7.50

Surprise

-229.53%

Minerva Neurosciences, Inc

Report Date

Mar 11, 2026 For Q4 25

Estimate

-$0.30

Actual

-$0.64

Surprise

-109.15%

Century Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.28

Actual

-$0.22

Surprise

+23.88%

Tonix Pharmaceuticals Holding Corp.

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$3.25

Actual

-$3.98

Surprise

-22.32%

Korro Bio, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$2.10

Actual

-$1.65

Surprise

+21.74%

Verrica Pharmaceuticals Inc. Common Stock

Report Date

Mar 11, 2026 For Q4 25

Estimate

-$0.81

Actual

-$0.46

Surprise

+43.22%

Champions Oncology, Inc.

Report Date

Mar 12, 2026 For Q3 26

Estimate

$0.09

Actual

-$0.02

Surprise

-121.79%

Oruka Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.64

Actual

-$0.45

Surprise

+29.69%

FAQ

What were Xencor, Inc.'s earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Xencor, Inc. reported EPS of -$0.09, beating estimates by 85.37%, and revenue of $28.24M, -12.63% below expectations.

How did the market react to Xencor, Inc.'s Q4 2025 earnings?

The stock price moved up 13.11%, changed from $11.98 before the earnings release to $13.55 the day after.

When is Xencor, Inc. expected to report next?

The next earning report is scheduled for May 05, 2026.

What are the forecasts for Xencor, Inc.'s next earnings report?

Based on 11 analysts, Xencor, Inc. is expected to report EPS of -$0.75 and revenue of $32.30M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.